Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol

Lancet

Volumn 359, Issue 9311, 2002, Pages 1004-1010

  Lindholm, Lars H ^a   Ibsen, Hans ^b   Dahlöf, Björn ^c   Devereux, Richard B ^d   Beevers, Gareth ^e   De Faire, Ulf ^f   Fyhrquist, Frej ^g   Julius, Stevo ^h   Kjeldsen, Sverre E ⁱ   Kristiansson, Krister ^j   Lederballe Pedersen, Ole ^k   Nieminen, Markku S ^g   Omvik, Per ^l   Oparil, Suzanne ^m   Wedel, Hans ⁿ   Aurup, Peter ^o   Edelman, Jonathan ^o   Snapinn, Steven ^o  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d WEILL CORNELL MEDICAL CENTER   (United States)

^e CITY HOSPITAL   (United Kingdom)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h UNIVERSITY OF MICHIGAN   (United States)

ⁱ ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^j Merck Research Laboratories Scandinavia   (Sweden)

^k VIBORG HOSPITAL   (Denmark)

^l HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^o MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN II ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; INSULIN; LOSARTAN; PLACEBO; SULFONYLUREA;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; ASTHENIA; BRADYCARDIA; CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLD LIMB; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPNEA; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEADACHE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; MORBIDITY; MORTALITY; NAUSEA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; STROKE; THORAX PAIN; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERTIGO;

EID: 0037160969     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)08090-X     Document Type: Article

References (30)

1. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
2. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: Rationale, design, and methods
3. Characteristics of 9,194 patients with left ventricular hypertrophy: The LIFE study
4. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: The LIFE study
5. Diabetes and cardiovascular risk factors in the Framingham study
6. Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in multiple risk factor intervention trial
7. Global and societal implications of the diabetic epidemic
8. An updated coronary risk profile: A statement for health professionals
9. Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older patients with isolated systolic hypertension
10. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM
11. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension
12. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
13. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
14. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension
15. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
16. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy
17. Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: Results from the Swedish Trial in Old Patients with Hypertension-2
18. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study
19. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT)
20. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study Investigators
21. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
22. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
23. Impact of diabetes on cardiac structure and function: The Strong Heart Study
24. Impact of type II diabetes on left ventricular geometry and function: The Hypertension Genetic Epidemiology Network (HyperGEN) Study
25. Separate and joint effects of hypertension and diabetes mellitus on left ventricular structure and function: The Strong Heart Study
26. Cardiovascular disease and prognosis in adults with glucose disorders: The Strong Heart Study
27. World Health Organisation-International Society of Hypertension guidelines for the management of hypertension
28. The renin-angiotensin-aldosterone system: A specific target for hypertension management
29. Diabetic nephropathy